Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 22:2022:6093092.
doi: 10.1155/2022/6093092. eCollection 2022.

Seasonal Variation of Testosterone Levels in a Large Cohort of Men

Taiba Zornitzki  1   2 , Sagi Tshori  2   3 , Galit Shefer  2   3 , Shira Mingelgrin  2   3 , Carmit Levy  4 , Hilla Knobler  1   2
Affiliations

Seasonal Variation of Testosterone Levels in a Large Cohort of Men

Taiba Zornitzki et al. Int J Endocrinol. .

Abstract

Objectives: The aim of the study was to evaluate in a large cohort of males with a wide range of age, metabolic status, and coexistent morbidities whether month of blood test performance was associated with total and bioavailable testosterone levels independent of age, body mass index (BMI), existing cardiovascular disease (CVD), and CVD risk factors.

Methods: Cross-sectional study includes data from computerized medical records of 27,328 men aged 20-70, treated by the largest healthcare organization in Israel, who had undergone testosterone measurement. In 7,940 subjects with available sex-hormone-binding globulin levels, bioavailable testosterone was calculated.

Results: Total and bioavailable testosterone levels gradually decreased with age and BMI (P < 0.001) and were significantly lower in men with diabetes, hypertension, hyperlipidemia, and known CVD, but were higher in current smokers compared with nonsmokers (P < 0.001). Hormone levels were highest in August-October declined after and lowest in March. Overall, both total and bioavailable testosterone levels were significantly lower in March compared to August-October (P < 0.001). In a linear regression analysis, age, BMI, current smoking, and month of testing were independently associated with total (P < 0.001) and bioavailable testosterone levels (P=0.002), and diabetes was associated with total testosterone (P < 0.001).

Conclusion: In a large cohort of men with a wide range of age, BMI, and comorbidities, month of testing was independently associated with total and bioavailable testosterone levels. These data provide strong evidence that seasonal variation has to be considered in clinical practice.

PubMed Disclaimer

Conflict of interest statement

None of the authors has any conflicts of interest.

Figures

Figure 1
Figure 1
Monthly variations in total and bioavailable testosterone levels in a cohort of men aged 20–70.
See this image and copyright information in PMC

References

    1. Morgentaler A., Miner M. M., Caliber M., Guay A. T., Khera M., Traish A. M. Testosterone therapy and cardiovascular risk: advances and controversies. Mayo Clinic Proceedings . 2015;90(2):224–251. doi: 10.1016/j.mayocp.2014.10.011. - DOI - PubMed
    1. Walsh J. P., Kitchens A. C. Testosterone therapy and cardiovascular risk. Trends in Cardiovascular Medicine . 2015;25(3):250–257. doi: 10.1016/j.tcm.2014.10.014. - DOI - PubMed
    1. Corona G., Rastrelli G., Di Pasquale G., Sforza A., Mannucci E., Maggi M. Testosterone and cardiovascular risk: meta-analysis of interventional studies. The Journal of Sexual Medicine . 2018;15(6):820–838. doi: 10.1016/j.jsxm.2018.04.641. - DOI - PubMed
    1. Wallis C. J. D., Lo K., Lee Y., et al. Survival and cardiovascular events in men treated with testosterone replacement therapy: an intention-to-treat observational cohort study. Lancet Diabetes & Endocrinology . 2016;4(6):498–506. doi: 10.1016/s2213-8587(16)00112-1. - DOI - PubMed
    1. Wittert G., Bracken K., Robledo K. P., et al. Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial. Lancet Diabetes & Endocrinology . 2021;9(1):32–45. doi: 10.1016/s2213-8587(20)30367-3. - DOI - PubMed

LinkOut - more resources